T
Tangen Biosciences
Portable molecular diagnostics for rapid infectious disease detection
About Tangen Biosciences
Tangen Biosciences, Inc. is a molecular diagnostics company founded in 2013 by John Davidson and headquartered in Branford, Connecticut. The company focuses on decentralizing diagnostics by moving molecular testing from traditional laboratories to point-of-care settings like doctor's offices, pharmacies, and clinics in remote areas. The co-founders, including John Davidson (Chief Science Officer) and John Nobile, have extensive experience in developing next-generation DNA sequencing technologies at companies like Roche and Life Technologies. The leadership team was later joined by CEO Richard C. Birkmeyer, PhD, a seasoned executive with a track record of leading diagnostic startups to successful exits.
The company's core technology is the TangenDx™ platform, which consists of a portable, automated instrument called the GeneSpark™ analyzer and single-use disposable test discs. This platform utilizes isothermal nucleic acid amplification to rapidly detect targeted DNA and RNA from various patient samples, such as whole blood, swabs, and sputum, delivering results in under an hour without needing complex laboratory equipment or refrigerated reagents. A key differentiator is the system's ability to simultaneously detect a broad array of targets from a single sample with high sensitivity and a simple workflow.
Tangen Biosciences' business model centers on the development and sale of these diagnostic test kits for its platform. The company serves healthcare providers who require rapid, on-site diagnostics for infectious diseases. Its product pipeline includes tests for bloodstream infections (sepsis), respiratory viruses like SARS-CoV-2 and Influenza A/B, and antimicrobial resistance (AMR) gene panels. The firm gained significant attention during the COVID-19 pandemic, developing a point-of-care test and receiving federal contracts and an Emergency Use Authorization from the FDA. The business generates revenue through the sale of its GeneSpark instruments and the disposable assay kits. Tangen has successfully raised capital through multiple funding rounds, including a $46.6M total from investors like Connecticut Innovations, Leading Edge Ventures, and Parvizi Surgical Innovation, to scale manufacturing and accelerate clinical development.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Tangen Biosciences is 50 monthly website visits, down 92.3% over the last three months. Tangen Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tangen Biosciences in the Branford ecosystem
The Tangen Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
HHS Administration for Strategic Preparedness and Response
Series A5 investors entered at this stage
- AVAxiom Ventures
Connecticut Innovations- LVLeading Edge Ventures
- VCVC23
Parvizi Surgical Innovation
Other known investors1 additional known investor
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tangen Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tangen Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










